NCT07518342

Brief Summary

Androgenetic alopecia is a condition that bothers a lot of people. The disadvantage of the FDA approved topical minoxidil is that the patient needs to be compliant every day for extended periods of time. This is the main reason why this study is being conducted, to see if a single nanofat injection is superior to applying either topical Minoxidil or PRP

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for phase_4

Timeline
29mo left

Started Apr 2026

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress13%
Apr 2026Dec 2028

First Submitted

Initial submission to the registry

March 29, 2026

Completed
3 days until next milestone

Study Start

First participant enrolled

April 1, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 8, 2026

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2028

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2028

Last Updated

April 13, 2026

Status Verified

March 1, 2026

Enrollment Period

2.2 years

First QC Date

March 29, 2026

Last Update Submit

April 8, 2026

Conditions

Androgenetic AlopeciaAndrogenetic Alopecia (AGA)

Keywords

Androgenetic AlopeciaAlopeciaPRPnanofatnanofat injectionMinoxidilTopical minoxidil

Outcome Measures

Primary Outcomes (3)

  • Clinical improvement by using trichoscopy and photographs

    Photographs using Hamilton norwood scale for males and Ludwig Scale for females

    All patients will be evaluated at Day 1 and at 6, 12 and 16 weeks.

  • Trichoscopic improvement

    Including hair diameter diversity

    All patients will be evaluated at Day 1 and at 6, 12 and 16 weeks.

  • patient satisfaction score

    It will be used for objective evaluation: * 0 to 25% change = not satisfied, * 26 to 50% = mildly satisfied, * 51 to 75% = moderately satisfied, * 76 to 100% = very satisfied.

    All patients will be evaluated at Day 1 and at 6, 12 and 16 weeks.

Secondary Outcomes (1)

  • Temporal Hairline Position

    All patients will be evaluated at Day 1 and at 6, 12 and 16 weeks.

Study Arms (3)

Topical minoxidil 5/

ACTIVE COMPARATOR

Patients will be taught how to apply topical minoxidil daily for three months

Drug: Minoxidil 5 %

PRP injection

ACTIVE COMPARATOR

Patients will receive three PRP injections one month apart each

Procedure: PRP injection

nanofat injection

EXPERIMENTAL

Patience well receive single nano fat injection

Procedure: Nanofat injection

Interventions

PRP injectionPROCEDURE

3 PRP injections one month apart

PRP injection
Nanofat injectionPROCEDURE

Single nanofat injection

nanofat injection
Minoxidil 5 %DRUG

Topical application of minoxidil 5%

Topical minoxidil 5/

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Adults (ages 18-50).
  • A clinical diagnosis of androgenetic alopecia confirmed by dermoscopy of both males and females.
  • No previous topical treatment used in the past 3 months.

You may not qualify if:

  • Alopecia totalis and alopecia universalis.
  • Cicatricial alopecia.
  • Other causes of hair loss such as immunological disease.
  • Skin disease in the affected area.
  • Hypersensitivity or allergy to any of the treatment products used.
  • Patients using treatment (topical or systemic) for androgenetic alopecia in the last 3 months.
  • Pregnant and lactating females.
  • Patients with a history of hypertrophic scars or keloid formation.
  • Patients with active infection at the site of the lesion.
  • Skin disease in the affected area.
  • Hamilton norwood scale stage 6 and 7
  • Ludwig Scale stage 3

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut University

Asyut, Egypt

Location

Related Publications (11)

  • Stevens J,Khetarpal S

    BACKGROUND

  • Coleman SR. Structural fat grafting: more than a permanent filler. Plast Reconstr Surg. 2006 Sep;118(3 Suppl):108S-120S. doi: 10.1097/01.prs.0000234610.81672.e7.

    PMID: 16936550BACKGROUND

  • Zhang Z, Chen N, Xiao L, Li K, Liu H. Injection of the Concentrate Derived from Nanofat Graft Promotes Hair Growth in Patients of Male Androgenetic Alopecia: A Clinical Pilot Study. Aesthetic Plast Surg. 2025 Oct;49(19):5548-5558. doi: 10.1007/s00266-025-05291-z. Epub 2025 Sep 30.

    PMID: 41028613BACKGROUND

  • Awasthi C, Khan A, Islam SS. PdSe2/MoSe2: a promising van der Waals heterostructure for field effect transistor application. Nanotechnology. 2024 Feb 19;35(19). doi: 10.1088/1361-6528/ad2482.

    PMID: 38295411BACKGROUND

  • Xia Y, Chen H, Chen Y, Chen Z. Relative efficacy of minoxidil in combination with other treatments for androgenic alopecia: a network meta-analysis based on randomized controlled trials. Front Med (Lausanne). 2025 Sep 17;12:1638496. doi: 10.3389/fmed.2025.1638496. eCollection 2025.

    PMID: 41041440BACKGROUND

  • Suchonwanit P,Thammarucha S,Leerunyakul K

    BACKGROUND

  • Ho CH, Sood T, Zito PM. Androgenetic Alopecia. 2024 Jan 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK430924/

    PMID: 28613674BACKGROUND

  • Kaiser M, Abdin R, Gaumond SI, Issa NT, Jimenez JJ. Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs. Clin Cosmet Investig Dermatol. 2023 May 31;16:1387-1406. doi: 10.2147/CCID.S385861. eCollection 2023.

    PMID: 37284568BACKGROUND

  • Wang Y, Ding W, Yao M, Li Y, Wang M, Wang L, Li Z, Sun S, Yang M, Zhu Y, Zhou N. Diagnostic and grading criteria for androgenetic alopecia using dermoscopy. Skin Res Technol. 2024 Apr;30(4):e13649. doi: 10.1111/srt.13649.

    PMID: 38533753BACKGROUND

  • Al Sayed NM, El Morsy EH, Hussein TM, Hassan EM. Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in Female Pattern Hair Loss Treatment. Dermatol Pract Concept. 2025 Jan 30;15(1):4698. doi: 10.5826/dpc.1501a4698.

    PMID: 40117614BACKGROUND

  • Kuczara A,Waśkiel-Burnat A,Rakowska A,Olszewska M,Rudnicka L

    BACKGROUND

MeSH Terms

Conditions

Alopecia

Condition Hierarchy (Ancestors)

HypotrichosisHair DiseasesSkin DiseasesSkin and Connective Tissue DiseasesPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Officials

  • Hanan Ahmed Morsy, Professor Doctor

    Assiut University

    STUDY CHAIR

  • Reham Maher Abdel Gaber, Doctor

    Assiut University

    STUDY DIRECTOR

Central Study Contacts

Marina Aiad Aboelsaad, Bachelor of Medicine and Surge

CONTACT

+201282347199marina.aiad16@gmail.com

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant lecturer

Study Record Dates

First Submitted

March 29, 2026

First Posted

April 8, 2026

Study Start

April 1, 2026

Primary Completion (Estimated)

June 1, 2028

Study Completion (Estimated)

December 1, 2028

Last Updated

April 13, 2026

Record last verified: 2026-03

Locations

EG(1)